Ground was supposed to have been broken in the fourth quarter of 2008, according to Tower Investments. Now, after delays and increasing skepticism from the public, John Pierce, senior vice president at Tower Investments LLC, said that plans have changed.
This is the second major divestiture for AMS in the past six months. The Minnetonka-based company sold its Ovion sterilization technology to Mountain View, Calif.-based Conceptus Inc. for $23.6 million last October.
How Apella leverages technology to increase OR efficiency.
The difficulties Olmsted County plaintiffs face in pursuing a medical malpractice claim against the Mayo Clinic, by far the area’s largest employer, were apparent in a recent appellate court decision in Becker et al. v. Mayo Foundation. The case involved an appeal from an Olmsted County jury’s finding that the clinic was not negligent in failing to report suspected abuse of an infant.
The group practice has been planning a standalone treatment center for three years, but targeted the east metro suburb after failing to negotiate a contract to staff the Woodwinds ER.
Medica Encore is targeted at the pre-retirement boomer generation ages 50 to 64 who lack traditional health coverage through employers or other group sponsors, the company says.
Perhaps UnitedHealth and Continuum should get back to the business of negotiating a contract instead of competing in a bizarre Ms. Popularity Contest, a crown that belongs to neither of them.
Sheila Bond, MD, talked about the latest trends regarding integration of AI in healthcare.
Access Genetics, based in Eden Prairie, has taken it one step further by allowing doctors with different expertise, like urologists and OBGYNs, to view DNA test results and collaborate on diagnosis and treatment -- all through a special Web site and virtual software.
The first patient in NeoChord Inc.'s European clinical trial has been implanted with an artificial chord to treat his faulty heart valve.
The company is developing a series of nails, surgical instruments and a drill that combined would work faster and do a better job of fastening screws in place during surgery. Also, the company thinks its process will cut down on the number of X-Rays needed to confirm success of such procedures, and slash by half the time needed for the operation.
Impres' device goes into the bottom of the uterus and deactivates the patient’s menstrual period. It's specifically focused on women who won't have any more children and works as an alternative to hysterectomy or endometrial ablation, a process that which destroys the lining of the womb.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
NeoChord Inc. in Minnetonka, Minn., has raised at least $2.8 million to help it continue to develop a novel way of enabling surgeons to repair bad mitral valves in patients' hearts.